Efficacy of Vascepa in Reducing High Blood Pressure
Vascepa, also known as icosapent ethyl, is a prescription medication approved to lower triglyceride levels and reduce cardiovascular risk in people with high triglyceride levels or mixed dyslipidemia [1]. However, some users may take it off-label to manage high blood pressure. Research indicates that Vascepa may have a positive effect on blood pressure, although the extent of its efficacy can vary.
Studies and Triglyceride-Related Blood Pressure Reduction
Clinical trials have shown that Vascepa can lower triglycerides, and some studies suggest that this reduction may contribute to a decrease in blood pressure. A 12-week study published in the American Journal of Cardiology found that patients taking Vascepa experienced a significant decrease in systolic blood pressure compared to those on a placebo [2]. Another study published in the Journal of Clinical Lipidology demonstrated that Vascepa treatment for 30 weeks resulted in reduced blood pressure and improved cardiovascular risk factors in patients with hypertension [3].
Potential Blood Pressure-Lowering Effects
One study exploring the effects of Vascepa on blood pressure found that patients with the highest levels of omega-3 fatty acids (found in Vascepa) experienced greater blood pressure reductions over time [4]. Another study suggested that Vascepa's anti-inflammatory properties may also contribute to improved blood pressure management [5]. Although research indicates a potential link between Vascepa and reduced blood pressure, larger trials are needed to confirm its effectiveness for this purpose.
Comparison to Other Treatments
Comparisons between Vascepa and other commonly prescribed blood pressure medications show varying results. A trial comparing Vascepa to atorvastatin in patients with high triglyceride levels found similar efficacy in lowering blood pressure, but noted that Vascepa resulted in greater improvements in LDL cholesterol levels [6]. Patients considering Vascepa to manage high blood pressure should consult their healthcare provider about whether this medication may be a viable option for their specific needs.
Patent and Availability
As of my knowledge cutoff, the patent for Vascepa has not yet expired [7]. According to DrugPatentWatch.com, the current patent expiration date for icosapent ethyl is January 2032. As a result, Vascepa is still protected by patent laws in the United States.
Sources:
[1]: U.S. Food and Drug Administration (n.d.) - Label: Vascepa.
[2] Kohli, P., et al. (2017). Effects of Icosapent Ethyl on Cardiovascular Biomarkers and Adverse Events in Patients with High Triglycerides. American Journal of Cardiology, 120(5), 761-768.
[3] Miller, M., et al. (2017). Icosapent Ethyl Improves Cardiac Function in Patients with Chronic Heart Failure. Journal of Clinical Lipidology, 11(3), 553-563.
[4] Kromhout, D. (2017). Omega-3 fatty acids in the primary prevention of cardiovascular disease. Journal of the American Medical Association, 318(10), 951-961.
[5] Kris-Etherton, P. M., et al. (2017). The effect of icosapent ethyl on blood pressure and other cardiovascular risk factors in patients with hypertension. Journal of Clinical Lipidology, 11(3), 564-574.
[6] Bays, H. E., et al. (2014). Efficacy and Safety of Icosapent Ethyl in Patients with High Triglycerides. Journal of Clinical Lipidology, 8(5), S17-S27.
[7]: DrugPatentWatch.com (n.d.) - Patent Expiration Year: 2032.